{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:55:54Z","timestamp":1790596554722,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75733-y","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:09Z","timestamp":1787786049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2\/3 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Jiayu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1233-6081","authenticated-orcid":false,"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofeng","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue\u2019e","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenran","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"75733_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1055-9965.EPI-18-0591","volume":"28","author":"J Xie","year":"2019","unstructured":"Xie, J. & Xu, Z. A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer. Cancer Epidemiol. Biomark. Prev. 28, 283\u2013292 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"75733_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/annonc\/mdw036","volume":"27","author":"ES Lee","year":"2016","unstructured":"Lee, E. S. et al. Identifying the potential long-term survivors among breast cancer patients with distant metastasis. Ann. Oncol. 27, 828\u2013833 (2016).","journal-title":"Ann. Oncol."},{"key":"75733_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.breast.2017.02.003","volume":"32","author":"TG Yoo","year":"2017","unstructured":"Yoo, T. G. et al. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: is there a survival benefit? Breast 32, 162\u2013172 (2017).","journal-title":"Breast"},{"key":"75733_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.2025.43.16_suppl.1029","volume":"43","author":"CR Lemech","year":"2025","unstructured":"Lemech, C. R. et al. IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: updates from a phase 1 study. J. Clin. Oncol. 43, 1029\u20131029 (2025).","journal-title":"J. Clin. Oncol."},{"key":"75733_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2024.42.16_suppl.1020","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. ACE-Breast-02: a pivotal phase II\/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). J. Clin. Oncol. 42, 1020\u20131020 (2024).","journal-title":"J. Clin. Oncol."},{"key":"75733_CR6","doi-asserted-by":"publisher","first-page":"S1569","DOI":"10.1016\/j.annonc.2025.09.034","volume":"36","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. LBA24 Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: results from a randomized phase III study. Ann. Oncol. 36, S1569 (2025).","journal-title":"Ann. Oncol."},{"key":"75733_CR7","unstructured":"National Comprehensive Cancer Network. Breast Cancer, version 1.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419. Accessed on February 10, 2026."},{"key":"75733_CR8","unstructured":"Chinese Society of Clinical Oncology Breast Cancer Guidelines in 2025. http:\/\/www.csco.ac.cn\/. Accessed on February 10, 2026."},{"key":"75733_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med"},{"key":"75733_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208\u20132215 (2024).","journal-title":"Nat. Med."},{"key":"75733_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/tbcr-23-2","volume":"4","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy. Transl. Breast Cancer Res. 4, 3 (2023).","journal-title":"Transl. Breast Cancer Res."},{"key":"75733_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med"},{"key":"75733_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 351\u2013360 (2021).","journal-title":"Lancet Oncol."},{"key":"75733_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","volume":"153","author":"X Yao","year":"2015","unstructured":"Yao, X. et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res. Treat. 153, 123\u2013133 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"75733_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","volume":"17","author":"H Li","year":"2016","unstructured":"Li, H. et al. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol. Ther. 17, 346\u2013354 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"75733_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"75733_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng, Z. et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. (Lond.) 41, 1173\u20131182 (2021).","journal-title":"Cancer Commun. (Lond.)"},{"key":"75733_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cac2.12577","volume":"44","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study. Cancer Commun. 44, 833\u2013851 (2024).","journal-title":"Cancer Commun."},{"key":"75733_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1723716","volume":"15","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Deviating HER2 status between primary breast carcinomas and their liver metastases. Front Oncol. 15, 1723716 (2025).","journal-title":"Front Oncol."},{"key":"75733_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00761-021-01070-y","volume":"28","author":"H-J Stemmler","year":"2005","unstructured":"Stemmler, H.-J. et al. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab. Onkologie 28, 95\u201397 (2005).","journal-title":"Onkologie"},{"key":"75733_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.5599\/admet.2582","volume":"13","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin. Admet dmpk 13, 2582 (2025).","journal-title":"Admet dmpk"},{"key":"75733_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10585-021-10080-4","volume":"38","author":"NS Rashid","year":"2021","unstructured":"Rashid, N. S. et al. Breast cancer liver metastasis: current and future treatment approaches. Clin. Exp. Metastasis 38, 263\u2013277 (2021).","journal-title":"Clin. Exp. Metastasis"},{"key":"75733_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105\u2013117 (2023).","journal-title":"Lancet"},{"key":"75733_CR24","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C. E. et al. Lapatinib plus Capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733\u20132743 (2006).","journal-title":"N. Engl. J. Med."},{"key":"75733_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman, R. L. et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 609\u2013619 (2021).","journal-title":"Lancet Oncol."},{"key":"75733_CR26","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"75733_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct. Target. Ther. 10, 56 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"75733_CR28","unstructured":"Guideline for HER2 detection in breast cancer, the 2019 version. Chinese J. Pathol. 48, 169\u2013175 (2019)."},{"key":"75733_CR29","doi-asserted-by":"crossref","unstructured":"Mehta, C. R. & Pocock, S. J. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat. Med. 30, 3267\u20133284 (2011).","DOI":"10.1002\/sim.4102"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75733-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:03:18Z","timestamp":1790593398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75733"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75733-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shanshan Gu, Dandan Gao, Zerui Qu, and Chenran Han were employees of RemeGen. Jianmin Fang is a shareholder of RemeGen. The other authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10236"}}